Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of Pituitary adenomas: a cross-sectional study in the Province of Liège, Belgium. J Clin Endocrinol Metabolism 91(12):4769–4775. https://doi.org/10.1210/jc.2006-1668
Ferrante E, Ferraroni M, Castrignanò T, Menicatti L, Anagni M, Reimondo G, Del Monte P, Bernasconi D, Loli P, Faustini-Fustini M, Borretta G, Terzolo M, Losa M, Morabito A, Spada A, Beck-Peccoz P, Lania AG (2006) Non-functioning Pituitary Adenoma database: a useful resource to improve the Clinical Management of Pituitary tumors. eur j Endocrinol 155(6):823–829. https://doi.org/10.1530/eje.1.02298
Article CAS PubMed Google Scholar
Molitch ME, Pituitary, Incidentalomas (2009) Best Pract Res Clin Endocrinol Metab 23(5):667–675. https://doi.org/10.1016/j.beem.2009.05.001
Article CAS PubMed Google Scholar
Huang W, Molitch ME (2018) Management of nonfunctioning pituitary adenomas (NFAs): Observation. Pituitary 21(2):162–167. https://doi.org/10.1007/s11102-017-0856-0
Yavropoulou MP, Tsoli M, Barkas K, Kaltsas G, Grossman A (2020) The natural history and treatment of non-functioning Pituitary Adenomas (Non-functioning PitNETs). Endocrine-related Cancer 27(10):R375–R390. https://doi.org/10.1530/ERC-20-0136
Article CAS PubMed Google Scholar
Molitch ME (2014) Nonfunctioning pituitary tumors. In handbook of clinical neurology. Elsevier 124:167–184. https://doi.org/10.1016/B978-0-444-59602-4.00012-5
Greenman Y, Stern N (2015) Optimal management of non-functioning pituitary adenomas. Endocrine 50(1):51–55. https://doi.org/10.1007/s12020-015-0685-8
Article CAS PubMed Google Scholar
Greenman Y, Cooper O, Yaish I, Robenshtok E, Sagiv N, Jonas-Kimchi T, Yuan X, Gertych A, Shimon I, Ram Z, Melmed S, Stern N (2016) Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol 175(1):63–72. https://doi.org/10.1530/EJE-16-0206
Article CAS PubMed Google Scholar
Dekkers OM, Hammer S, de Keizer RJW, Roelfsema F, Schutte PJ, Smit JWA, Romijn JA, Pereira AM (2007) The natural course of non-functioning Pituitary Macroadenomas. eur j Endocrinol 156(2):217–224. https://doi.org/10.1530/eje.1.02334
Article CAS PubMed Google Scholar
Lenders N, Ikeuchi S, Russell AW, Ho KK, Prins JB, Inder WJ (2016) Longitudinal evaluation of the natural history of conservatively managed nonfunctioning pituitary adenomas. Clin Endocrinol 84(2):222–228. https://doi.org/10.1111/cen.12879
Karavitaki N, Collison K, Halliday J, Byrne JV, Price P, Cudlip S, Wass JAH (2007) What is the natural history of Nonoperated Nonfunctioning Pituitary Adenomas? Clin Endocrinol 67(6):938–943. https://doi.org/10.1111/j.1365-2265.2007.02990.x
Ayalon-Dangur I, Robenshtok E, Duskin‐Bitan H, Tsvetov G, Gorshtein A, Akirov A, Shimon I (2023) Natural history of nonfunctioning Pituitary macroadenomas followed without intervention: a retrospective cohort study. Clin Endocrinol 98(4):559–566. https://doi.org/10.1111/cen.14877
Fernández-Balsells MM, Murad MH, Barwise A, Gallegos-Orozco JF, Paul A, Lane MA, Lampropulos JF, Natividad I, Perestelo-Pérez L, de Ponce PG, Erwin PJ, Carey J, Montori VM (2011) Natural history of nonfunctioning Pituitary adenomas and incidentalomas: a systematic review and metaanalysis. J Clin Endocrinol Metabolism 96(4):905–912. https://doi.org/10.1210/jc.2010-1054
Wang AT, Mullan RJ, Lane MA, Hazem A, Prasad C, Gathaiya NW, Fernández-Balsells MM, Bagatto A, Coto-Yglesias F, Carey J, Elraiyah TA, Erwin PJ, Gandhi GY, Montori VM, Murad MH (2012) Treatment of hyperprolactinemia: a systematic review and Meta-analysis. Syst Rev 1(1):33. https://doi.org/10.1186/2046-4053-1-33
Article CAS PubMed PubMed Central Google Scholar
Vieira Neto L, Wildemberg LE, Moraes AB, Colli LM, Kasuki L, Marques NV, Gasparetto EL, de Castro M, Takiya CM, Gadelha MR (2015) Dopamine receptor subtype 2 expression Profile in Nonfunctioning Pituitary adenomas and in vivo response to Cabergoline Therapy. Clin Endocrinol 82(5):739–746. https://doi.org/10.1111/cen.12684
Batista RL, Musolino NRC, Cescato VAS, da Silva GO, Medeiros RSS, Herkenhoff CGB, Trarbach EB, Cunha-Neto (2019) M. B. Cabergoline in the management of residual nonfunctioning pituitary adenoma: a Single-Center, Open-Label, 2-Year randomized clinical trial. Am J Clin Oncol 42(2):221–227. https://doi.org/10.1097/COC.0000000000000505
Article CAS PubMed Google Scholar
Vargas-Ortega G, González-Virla B, Balcázar-Hernández L, Arreola-Rosales R, Benitez-Rodríguez FJ, Félix BL, Mercado M (2022) Efficacy of Cabergoline Therapy in patients with non-functioning pituitary adenomas: a single Center Clinical Experience. Archives of Endocrinology and Metabolism. https://doi.org/10.20945/2359-3997000000495
Article PubMed PubMed Central Google Scholar
Garcia EC, Naves LA, Silva AO, de Castro LF, Casulari LA, Azevedo MF (2013) Short-term treatment with Cabergoline Can lead to Tumor Shrinkage in patients with nonfunctioning pituitary adenomas. Pituitary 16(2):189–194. https://doi.org/10.1007/s11102-012-0403-y
Article CAS PubMed Google Scholar
Ertekin T, Acer N, Turgut AT, Aycan K, Ozçelik O, Turgut M (2011) Comparison of three methods for the estimation of the Pituitary gland volume using magnetic resonance imaging: a Stereological Study. Pituitary 14(1):31–38. https://doi.org/10.1007/s11102-010-0254-3
Comments (0)